A phase 1, multicenter, open-label study to assess the effect of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) on QTc and pharmacokinetics in subjects with HER2-expressing metastatic and/or unresectable breast cancer

被引：3
作者：
Yamashita, Toshinari [1 ]
Shimomura, Akihiko [2 ]
Takano, Toshimi [3 ]
Sagara, Yasuaki [4 ]
Watanabe, Junichiro [5 ]
Tokunaga, Eriko [6 ]
Kikumori, Kunika [7 ]
Kamiyama, Emi [7 ]
Kamio, Takahiro [7 ]
Nakamura, Ryo [7 ]
Shinkai, Tetsu [8 ]
Takahashi, Shunji [9 ]
机构：
[1] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan
[2] Natl Canc Ctr, Tokyo, Japan
[3] Toranomon Gen Hosp, Tokyo, Japan
[4] Hakuaikai Sagara Hosp, Social Med Corp, Kagoshima, Japan
[5] Shizuoka Canc Ctr, Shizuoka, Japan
[6] Natl Hosp Org Kyushu Canc Ctr, Fukuoka, Japan
[7] Daiichi Sankyo Co Ltd, Tokyo, Japan
[8] Shonan Tobu Sougou Hosp, Kamakura, Kanagawa, Japan
[9] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS19-P1-18-12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-18-12
引用
收藏
页数：4
相关论文
共 50 条
  • [31] A phase 3, multicenter, randomized, open-label trial of trastuzumab deruxtecan (T-DXd; DS-8201) vs investigator's choice in HER2-low breast cancer (DESTINY-Breast04)
    Zaman, K.
    Modi, S.
    Ohtan, S.
    Lee, C.
    Wang, Y.
    Saxena, K.
    Cameron, D. A.
    SWISS MEDICAL WEEKLY, 2020, : 28S - 29S
  • [32] A phase 2 trial of trastuzumab deruxtecan (T-DXd, DS-8201) in patients with HER2-positive, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
    Fuchs, C.
    Shahidi, J.
    Mathew, L.
    Qin, A.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2020, 31 : S150 - S150
  • [33] Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study
    Hamilton, Erika
    Galsky, Matthew D.
    Ochsenreither, Sebastian
    Del Conte, Gianluca
    Martin, Miguel
    De Miguel, Maria Jose
    Yu, Evan Y.
    Williams, Anja
    Gion, Maria
    Tan, Antoinette R.
    Agrawal, Laila
    Rutten, Annemie
    Machiels, Jean-Pascal
    Cresta, Sara
    Debruyne, Philip R.
    Hennequin, Audrey
    Moreno, Victor
    Minchom, Anna
    Valdes-Albini, Frances
    Petrylak, Daniel
    Li, Li
    Tsuchihashi, Zenta
    Suto, Fumitaka
    Cheng, Fu-Chih
    Kandil, Maha
    Barrios, Daniel
    Hurvitz, Sara
    CLINICAL CANCER RESEARCH, 2024, 30 (24) : 5548 - 5558
  • [34] Primary analysis from DS8201-A-U105: A 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer
    Hamilton, E. P.
    Shapiro, C. L.
    Boni, V.
    Jimenez, M. Martin
    Del Conte, G.
    Cortes, J.
    Agrawal, L.
    Arkenau, H-T.
    Tan, A. R.
    Debruyne, P. R.
    Minchom, A. R.
    Rutten, A.
    Valdes-Albini, F.
    Yu, E.
    Suto, F.
    Cheng, F-C.
    Augustine, B.
    Cheng, B.
    Barrios, D.
    Hurvitz, S. A.
    ANNALS OF ONCOLOGY, 2022, 33 : S196 - S196
  • [35] Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC).
    Galsky, Matt D.
    Del Conte, Gianluca
    Foti, Silvia
    Yu, Evan Y.
    Machiels, Jean-Pascal H.
    Doger, Bernard
    Necchi, Andrea
    De Braud, Filippo G.
    Hamilton, Erika P.
    Hennequin, Audrey
    Van den Mooter, Tom
    Debruyne, Philip R.
    Moreno, Irene
    Arkenau, Hendrik-Tobias
    Tsuchihashi, Zenta
    Cheng, Fu-Chih
    Augustine, Bincy
    Cheng, Ben
    Barrios, Daniel
    Luftner, Diana
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [36] A phase II study of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-overexpressing or -mutated advanced non-small cell lung cancer
    Planchard, D.
    Li, B. T.
    Murakami, H.
    Shiga, R.
    Lee, C. C.
    Wang, K.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [37] Trastuzumab deruxtecan (T-DXd; DS-8201) combinations in patients with HER2-positive advanced or metastatic breast cancer: A phase 1b/2 open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07)
    Andre, Fabrice
    Hamilton, Erika
    Loi, Sherene
    Schmid, Peter
    Yu, Tinghui
    Lu, Shiyao
    Boston, Sarice
    D'Cruz, Celina
    Herbolsheimer, Pia
    Jhaveri, Komal
    CANCER RESEARCH, 2021, 81 (04)
  • [38] An open-label, multicenter, phase II study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) part 2
    Lee, J-Y
    Makker, V.
    Oaknin, A.
    Oh, D-Y
    Anoka, C.
    Jung, L.
    Simoes, J.
    Puvvada, S. D.
    Meric-Bernstam, F.
    ANNALS OF ONCOLOGY, 2024, 35 : S1553 - S1553
  • [39] Trastuzumab deruxtecan (T-DXd, DS-8201) in HER2-positive metastatic breast cancer previously treated with T-DM1: DESTINY-Breast01 Study
    Krop, I.
    Saura Manich, C.
    Yamashita, T.
    Park, Y. H.
    Kim, S. -B. K.
    Tamura, K.
    Andre, F.
    Iwata, H.
    Ito, Y.
    Tsurutani, J.
    Sohn, J.
    Denduluri, N.
    Perrin, C.
    Aogi, K.
    Tokunaga, E.
    Im, S. -A.
    Lee, K. S.
    Hurvitz, S.
    Cortes, J.
    Lee, C.
    Chen, S.
    Zhang, L.
    Shahidi, J.
    Yver, A.
    Modi, S.
    SWISS MEDICAL WEEKLY, 2020, : 25S - 25S
  • [40] An open-label, multicenter, phase II study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) part 2
    Lee, J-Y.
    Makker, V.
    Oaknin, A.
    Oh, D-y.
    Anoka, C.
    Jung, L.
    Simoes, J.
    Puvvada, S. D.
    Meric-Bernstam, F.
    ANNALS OF ONCOLOGY, 2024, 35
12345